Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.9
edited by Sarantis Dimitriadis
on 2022/06/07 08:54
Change comment: There is no comment for this version
To version 7.1
edited by Sarantis Dimitriadis
on 2023/05/30 09:35
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -7,6 +7,8 @@
7 7  (% class="western" lang="en-GB" style="text-align:justify" %)
8 8  (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following:
9 9  
10 +:
11 +
10 10  * (((
11 11  (% lang="en-US" %)**Non-professional end users:**
12 12  
... ... @@ -15,6 +15,8 @@
15 15  * (% lang="en-US" %)**Public health and social service clients: **Those who use public services.
16 16  )))
17 17  
20 +:
21 +
18 18  * (((
19 19  (% lang="en-US" %)**Professional end users**
20 20  
... ... @@ -25,9 +25,13 @@
25 25  * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level.
26 26  )))
27 27  
32 +:
33 +
28 28  (% class="western" lang="en-GB" %)
29 29  (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows:
30 30  
37 +:
38 +
31 31  * (((
32 32  (% lang="en-US" %)**Private sector organizations: **(business developers and researchers)
33 33  
... ... @@ -42,6 +42,8 @@
42 42  * (% lang="en-US" %)Pharmaceutical companies
43 43  )))
44 44  
53 +:
54 +
45 45  * (((
46 46  (% lang="en-GB" %)
47 47  (% lang="en-US" %)**Public sector organizations:**
... ... @@ -57,6 +57,8 @@
57 57  * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process.
58 58  )))
59 59  
70 +:
71 +
60 60  * (((
61 61  (% lang="en-GB" %)
62 62  (% lang="en-US" %)**Education and research organizations:**
... ... @@ -70,6 +70,8 @@
70 70  * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers
71 71  )))
72 72  
85 +:
86 +
73 73  * (((
74 74  (% lang="en-GB" %)
75 75  (% lang="en-US" %)**Civil society organizations:**
... ... @@ -77,6 +77,8 @@
77 77  * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level.
78 78  )))
79 79  
94 +:
95 +
80 80  * (((
81 81  (% lang="en-GB" %)
82 82  (% lang="en-US" %)**Networks and clusters:**
... ... @@ -88,13 +88,10 @@
88 88  :
89 89  
90 90  (% class="western" lang="en-GB" %)
91 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table .
107 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table .
92 92  
93 -(% style="margin-left:auto; margin-right:auto" %)
94 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)(((
95 -(% class="western" lang="en-GB" style="text-align:center" %)
96 -(% lang="en-US" %)**Age or age group**
97 -)))
109 +(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %)
110 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups**
98 98  |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
99 99  (% lang="en-US" %)Specific age range
100 100  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
... ... @@ -106,145 +106,47 @@
106 106  (% class="western" %)
107 107  
108 108  )))
109 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
110 -(% class="western" lang="en-GB" %)
111 -(% lang="en-US" %)Elderly
112 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
113 -(% class="western" lang="en-GB" %)
114 -(% lang="en-US" %)Adults
115 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
116 -(% class="western" lang="en-GB" %)
117 -(% lang="en-US" %)Youth
118 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
119 -(% class="western" lang="en-GB" %)
120 -(% lang="en-US" %)Children
121 -)))
122 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population
122 122  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
123 123  (% class="western" %)
124 124  
125 125  )))
126 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
127 -(% class="western" lang="en-GB" style="text-align:center" %)
128 -(% lang="en-US" %)**Health status**
129 -)))
127 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)**
130 130  |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
131 131  (% class="western" lang="en-GB" %)
132 132  (% lang="en-US" %)Healthy
133 133  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
134 134  (% class="western" lang="en-GB" %)
135 -(% lang="en-US" %)Patient
133 +
136 136  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
137 137  (% class="western" lang="en-GB" %)
138 -(% lang="en-US" %)Rehabilitant
136 +
139 139  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
140 140  (% class="western" lang="en-GB" %)
141 -(% lang="en-US" %)Recovered/Survivor
139 +
142 142  )))
143 143  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
144 144  (% class="western" %)
145 145  
146 146  )))
147 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
148 -(% class="western" lang="en-GB" style="text-align:center" %)
149 -(% lang="en-US" %)**A specific disease, disorder or disability**
150 -)))
151 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
152 -(% class="western" lang="en-GB" %)
153 -(% lang="en-US" %)ADHD
154 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
155 -(% class="western" lang="en-GB" %)
156 -(% lang="en-US" %)Dementia
157 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
158 -(% class="western" lang="en-GB" %)
159 -(% lang="en-US" %)Parkinsons’ disease
160 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
161 -(% class="western" lang="en-GB" %)
162 -(% lang="en-US" %)Loneliness and Social Isolation
163 -)))
164 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
165 -(% class="western" lang="en-GB" %)
166 -(% lang="en-US" %)Autism
167 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
168 -(% class="western" lang="en-GB" %)
169 -(% lang="en-US" %)Down syndrome
170 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
171 -(% class="western" lang="en-GB" %)
172 -(% lang="en-US" %)Physical disability
173 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
174 -(% class="western" lang="en-GB" %)
175 -(% lang="en-US" %)Mental health
176 -)))
177 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
178 -(% class="western" lang="en-GB" %)
179 -(% lang="en-US" %)Cardiovascular disease
180 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
181 -(% class="western" lang="en-GB" %)
182 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF)
183 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
184 -(% class="western" lang="en-GB" %)
185 -(% lang="en-US" %)Sleep apnea/apnea
186 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
187 -(% class="western" lang="en-GB" %)
188 -(% lang="en-US" %)Mild cognitive impairment
189 -)))
190 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
191 -(% class="western" lang="en-GB" %)
192 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD)
193 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
194 -(% class="western" lang="en-GB" %)
195 -(% lang="en-US" %)Language disability
196 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
197 -(% class="western" lang="en-GB" %)
198 -(% lang="en-US" %)Substance abuse (drugs, alcohol)
199 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
200 -(% class="western" lang="en-GB" %)
201 -(% lang="en-US" %)Multiple sclerosis
202 -)))
203 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
204 -(% class="western" lang="en-GB" %)
205 -(% lang="en-US" %)Cognitive disorder (mild, major)
206 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
207 -(% class="western" lang="en-GB" %)
208 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation
209 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
210 -(% class="western" lang="en-GB" %)
211 -(% lang="en-US" %)Trauma patient
212 -
213 -(% class="western" lang="en-GB" %)
214 -(% lang="en-US" %)(e.g., a spinal cord injury)
215 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
216 -(% class="western" lang="en-GB" %)
217 -(% lang="en-US" %)Neurodegenerative diseases
218 -)))
145 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)**
146 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Schizophrenia|Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Parkinson Disease
147 +|(% style="height:30px; width:153px" %)Post-Stroke Patients with Moving or Linguistic Disability|Mild Cognitive Impairment|Sleep Disorders: e.g., Apnea, Hypopnea|With Disability
148 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)
219 219  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
220 220  (% class="western" %)
221 221  
222 222  )))
223 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
224 -(% class="western" lang="en-GB" style="text-align:center" %)
225 -(% lang="en-US" %)**Clients of a specific service**
226 -)))
227 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
228 -(% class="western" lang="en-GB" %)
229 -(% lang="en-US" %)Child welfare
230 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
231 -(% class="western" lang="en-GB" %)
232 -(% lang="en-US" %)Nursing home
233 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
234 -(% class="western" lang="en-GB" %)
235 -(% lang="en-US" %)Employment service
236 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
153 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)**
154 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Parkinson Disease|Mild Cognitive Impairment|With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
237 237  (% class="western" %)
238 238  
239 239  )))
240 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
158 +|(% style="height:30px; width:153px" %)Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
241 241  (% class="western" lang="en-GB" %)
242 -(% lang="en-US" %)Early childhood education
160 +
243 243  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
244 244  (% class="western" lang="en-GB" %)
245 -(% lang="en-US" %)Home care
246 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
247 -(% class="western" lang="en-GB" %)
248 248  
249 249  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
250 250  (% class="western" lang="en-GB" %)
... ... @@ -254,70 +254,20 @@
254 254  (% class="western" %)
255 255  
256 256  )))
257 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
258 -(% class="western" lang="en-GB" style="text-align:center" %)
259 -(% lang="en-US" %)**Vulnerable groups**
260 -)))
261 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
172 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)**
173 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
262 262  (% class="western" lang="en-GB" %)
263 -(% lang="en-US" %)Minors/Children
264 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
265 -(% class="western" lang="en-GB" %)
266 -(% lang="en-US" %)Single parents with minor children
267 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
268 -(% class="western" lang="en-GB" %)
269 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence
270 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
271 -(% class="western" lang="en-GB" %)
272 -(% lang="en-US" %)Substance users
273 -
274 -(% class="western" lang="en-GB" %)
275 -(% lang="en-US" %)(drugs, alcohol)
175 +Down Syndrome
276 276  )))
277 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
278 278  (% class="western" lang="en-GB" %)
279 -(% lang="en-US" %)Disabled people
280 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
281 -(% class="western" lang="en-GB" %)
282 -(% lang="en-US" %)Victims of trafficking in human beings
283 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
284 -(% class="western" lang="en-GB" %)
285 -(% lang="en-US" %)Ethnic minorities and immigrants
286 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
287 -(% class="western" lang="en-GB" %)
288 -(% lang="en-US" %)Isolated people
289 -)))
290 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
291 -(% class="western" lang="en-GB" %)
292 -(% lang="en-US" %)Elderly people
293 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
294 -(% class="western" lang="en-GB" %)
295 -(% lang="en-US" %)Persons with serious illnesses
296 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
297 -(% class="western" lang="en-GB" %)
298 -(% lang="en-US" %)Homeless people
299 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
300 -(% class="western" lang="en-GB" %)
301 -(% lang="en-US" %)Ex-prisoners and people with criminal background
302 -)))
303 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; text-align:left; vertical-align:middle; width:153px" %)(((
304 -(% class="western" lang="en-GB" %)
305 -(% lang="en-US" %)Pregnant women
306 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
307 -(% class="western" lang="en-GB" %)
308 -(% lang="en-US" %)Persons with mental disorders
309 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
310 -(% class="western" lang="en-GB" %)
311 311  
312 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
313 -(% class="western" lang="en-GB" %)
314 -
315 315  )))
316 316  
317 317  :
318 318  
319 319  (% class="western" lang="en-GB" %)
320 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .
185 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) .
321 321  
322 322  |**Researcher expertise**|**Brief use case description**
323 323  |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101007990

Copyright © 2021 VITALISE Project